"The strength of our generic and proprietary product portfolios, our
commercial strength in important global markets, and our focus on
delivering sound results are among the benefits that make the proposed
acquisition of Barr by Teva, announced on July 18th, so attractive.
Management is committed to continuing to deliver strong performance as the
acquisition process progresses, to ensure that at the close of the
transaction, the capabilities of Barr will significantly complement Teva's
existing business," Downey continued.
Generic Product Sales
The Company's generic product sales were $557 million for the second
quarter of 2008, compared to $484 million in the prior year period. For the
first six months of 2008, generic product sales were $1.0 billion, compared
to $956 million for the prior year period. A discussion of the Company's
generic product sales for the second quarter of 2008 compared to the prior
year period is presented below.
Sales of North American generic products totaled $340 million for the
second quarter of 2008, compared to $296 million in the prior year period.
The increase in sales is primarily related to higher sales of generic oral
Sales of generic oral contraceptives increased 34% to $155 million in the
second quarter of 2008, up from $116 million in the prior year period.
The increase primarily reflects sales of Ocella(TM), the Company's generic
Yasmin(R) oral contraceptive product that was launched at the end of the
second quarter of 2008, which more than offset lower volume and pricing on
several other oral contraceptive
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved